Cell of Origin and Cancer Stem Cells in Tumor Suppressor Mouse Models of Glioblastoma

Cold Spring Harb Symp Quant Biol. 2016:81:31-36. doi: 10.1101/sqb.2016.81.030973. Epub 2016 Nov 4.

Abstract

The cellular origins and the mechanisms of progression, maintenance of tumorigenicity, and therapeutic resistance are central questions in the glioblastoma multiforme (GBM) field. Using tumor suppressor mouse models, our group recently reported two independent populations of adult GBM-initiating central nervous system progenitors. We found different functional and molecular subtypes depending on the tumor-initiating cell lineage, indicating that the cell of origin is a driver of GBM subtype diversity. Using an in vivo model, we also showed that GBM cancer stem cells (CSCs) or glioma stem cells (GSCs) contribute to resistance to chemotherapeutic agents and that genetic ablation of GSCs leads to a delay in tumor progression. These studies are consistent with the cell of origin and CSCs as critical regulators of the pathogenesis of GBM.

Publication types

  • Review
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Cell Proliferation / physiology*
  • Central Nervous System / cytology*
  • Disease Models, Animal*
  • Glioblastoma / drug therapy
  • Glioblastoma / pathology*
  • Humans
  • Mice
  • Neoplastic Stem Cells / cytology*
  • Neoplastic Stem Cells / drug effects

Substances

  • Antineoplastic Agents